Cargando…

Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety

Discrepancies between the medicines consumed by patients and those documented in the medical record can affect medication safety. We aimed to characterize medication discrepancies and medication regimen complexity over time in a cohort of outpatients with decompensated cirrhosis, and evaluate the im...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hayward, Kelly L., Valery, Patricia C., Patel, Preya J., Li, Catherine, Horsfall, Leigh U., Wright, Penny L., Tallis, Caroline J., Stuart, Katherine A., David, Michael, Irvine, Katharine M., Cottrell, Neil, Martin, Jennifer H., Powell, Elizabeth E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703811/ https://www.ncbi.nlm.nih.gov/pubmed/34959611 http://dx.doi.org/10.3390/ph14121207

Ejemplares similares

Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis
por: Hayward, Kelly L, et al.
Publicado: (2017)

Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention
por: Hayward, Kelly L., et al.
Publicado: (2019)

Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis
por: Hayward, Kelly L., et al.
Publicado: (2020)

Prevalence of medication discrepancies in patients with cirrhosis: a pilot study
por: Hayward, Kelly L., et al.
Publicado: (2016)

Patient‐oriented medication education intervention has long‐term benefits for people with decompensated cirrhosis
por: Hayward, Kelly L., et al.
Publicado: (2022)

Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial
por: Hayward, Kelly L., et al.
Publicado: (2017)

Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation
por: Gadd, Victoria L., et al.
Publicado: (2016)

Prescribing Medications in Patients with Decompensated Liver Cirrhosis
por: Amarapurkar, Deepak N.
Publicado: (2011)

Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
por: Irvine, Katharine M., et al.
Publicado: (2021)

Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests
por: Johnson, Amy L., et al.
Publicado: (2021)

Management options in decompensated cirrhosis
por: Shah, Neeral L, et al.
Publicado: (2015)

Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management
por: Patel, Preya Janubhai, et al.
Publicado: (2017)

Reply
por: Hayward, Kelly L., et al.
Publicado: (2019)

Development and Evaluation of the Supportive Needs Assessment Tool for Cirrhosis (SNAC)
por: Valery, Patricia C, et al.
Publicado: (2020)

ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies
por: Hayward, Kelly L, et al.
Publicado: (2020)

Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease
por: Patel, Preya J., et al.
Publicado: (2017)

Improving Survival in Decompensated Cirrhosis
por: Mukerji, Amar Nath, et al.
Publicado: (2012)

COVID-19 in decompensated cirrhosis
por: Rela, Mohamed, et al.
Publicado: (2020)

Decompensation of Cirrhosis: An Unusual Cause
por: Rudra, Omkar S, et al.
Publicado: (2022)

Improving Survival in Patients with Decompensated Cirrhosis
por: Amarapurkar, Deepak, et al.
Publicado: (2011)

Albumin in decompensated cirrhosis: new concepts and perspectives
por: Bernardi, Mauro, et al.
Publicado: (2020)

A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care
por: Patel, PreyaJanubhai, et al.
Publicado: (2018)

Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study
por: Johnson, Amy L, et al.
Publicado: (2021)

On the Discrepancy of Medical Opinions
por: Woodham, James
Publicado: (1814)

Poor disease knowledge is associated with higher healthcare service use and costs among patients with cirrhosis: an exploratory study
por: Valery, Patricia C., et al.
Publicado: (2022)

The Patient’s Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age
por: Valery, Patricia C., et al.
Publicado: (2021)

Causes and Consequences of Innate Immune Dysfunction in Cirrhosis
por: Irvine, Katharine Margaret, et al.
Publicado: (2019)

Treatment of Hepatitis B in Decompensated Liver Cirrhosis
por: Guan, Richard, et al.
Publicado: (2011)

Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
por: Amarapurkar, Pooja D., et al.
Publicado: (2011)

Glycated Hemoglobin Levels in Patients with Decompensated Cirrhosis
por: Nadelson, Jeffrey, et al.
Publicado: (2016)

Frequency of gallstones and mean BMI in decompensated cirrhosis
por: Rai, Ayesha Aslam, et al.
Publicado: (2018)

Clinical impact of microbiome in patients with decompensated cirrhosis
por: Oikonomou, Theodora, et al.
Publicado: (2018)

Micronutrient Deficiencies in Patients with Decompensated Liver Cirrhosis
por: Llibre-Nieto, Gemma, et al.
Publicado: (2021)

Acute Myeloid Leukemia Masquerading as Decompensated Cirrhosis
por: Ahdi, Hardeep S, et al.
Publicado: (2022)

Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis
por: Gurbuz, Berivan, et al.
Publicado: (2023)

Antimicrobial prophylaxis in decompensated cirrhosis: friend or foe?
por: Crocombe, Dominic, et al.
Publicado: (2023)

SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
por: Kaplan, David E., et al.
Publicado: (2021)

Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study
por: Ji, Fanpu, et al.
Publicado: (2017)

Efficacy and Safety of Sofosbuvir-based Regimens in Hepatitis C Patients With Decompensated Cirrhosis: A Systematic Review and Meta-analysis
por: Zhang, Wenyan, et al.
Publicado: (2023)

Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event
por: Balcar, Lorenz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vboduqi320fkjhn10uf612v7m8